Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you consider a targeted agent for a patient with ATM-mutant stage IV gallbladder cancer with peritoneal implants?
Also is there any role for HiPec if patient is stable on systemic therapy?
Related Questions
What are your top takeaways from ESMO 2023?
Would you typically offer adjuvant FOLFOX or XELOX to a pT4b pN0 colon cancer?
How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?
How would you manage a positive margin after APR for a patient who received neoadjuvant CAPOX alone due to previous remote prostate cancer radiation?
How would you approach treating a patient who refuses surgery, but has significant residual disease after chemoradiotherapy for squamous cell carcinoma of the esophagus?
Would you give adjuvant pembrolizumab in a MSI-H oligometastatic colorectal cancer status-post resection that responded to neoadjuvant ICI?
Would you consider Trastuzumab Deruxtecan as a second line option for metastatic HER2+ squamous cell carcinoma of the esophagus after progression on FOLFOX + Nivolumab?
In patients with resected PDAC treated with adjuvant FOLFIRINOX who recur from 1-3 years post completion of adjuvant therapy, do you consider retreatment with FOLFIRINOX or gemcitabine/nab-paclitaxel in the absence of a clinical trial?
How do you sequence HER2-therapy in HER2+ biliary tract cancer with the positive results of tucatinib + trastuzumab and zanidatamab in phase 2 studies?
How will the PROSPECT trial presented at ASCO 2023 change your current management of early rectal cancer?